CymaBay Therapeutics scraps two studies of liver drug; shares plunge

CymaBay Therapeutics Inc said on Monday it was scrapping two mid-stage trials of its liver disease drug, after biopsies found a type of liver damage in some patients, sending its shares down over 75%.

from Reuters: Health News https://ift.tt/2OLZYv9